L
Lorraine K. Webster
Researcher at Peter MacCallum Cancer Centre
Publications - 64
Citations - 2069
Lorraine K. Webster is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Chemotherapy & Paclitaxel. The author has an hindex of 28, co-authored 64 publications receiving 2017 citations. Previous affiliations of Lorraine K. Webster include University of Melbourne & University of St Andrews.
Papers
More filters
Journal ArticleDOI
Reversal of multidrug resistance by surfactants.
D. M. Woodcock,M. E. Linsenmeyer,G. Chojnowski,A. B. Kriegler,V. Nink,Lorraine K. Webster,W. H. Sawyer +6 more
TL;DR: In this article, Cremophor EL, a pharmacologically inactive solubilising agent, has been shown to reverse multidrug resistance (MDR) using flow cytometric evaluation of equilibrium intracellular levels of daunorubicin (DNR), using eight other surface active agents will also reverse MDR.
Journal ArticleDOI
Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Lorraine K. Webster,Martha E. Linsenmeyer,Michael Millward,Carmel G. Morton,James F. Bishop,David M. Woodcock +5 more
TL;DR: The efficacy of paclitaxel against some tumors may be aided by its administration in a vehicle solution containing Cremophor in quantities that reach concentrations in the plasma sufficient to reverse multidrug resistance of neoplastic cells.
Journal ArticleDOI
Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.
Andrew G. Ellis,M.M. Doherty,Francesca Walker,Janet Weinstock,Maureen Nerrie,Angela A. Vitali,Roger Murphy,Terrance Grant Johns,Andrew M. Scott,Alexander Levitzki,G. McLachlan,Lorraine K. Webster,Antony W. Burgess,Edouard C. Nice +13 more
TL;DR: The tyrphostin 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) is a potent and specific inhibitor of EGFR tyrosine kinase whose favourable preclinical profile supports progression towards clinical trials.
Journal ArticleDOI
Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness.
Trevor W. Hambley,Andrew R. Battle,Glen B. Deacon,Eric T. Lawrenz,Gary D. Fallon,B. M. Gatehouse,Lorraine K. Webster,Silvina Rainone +7 more
TL;DR: Reduction potentials of the series of complexes reveal that replacement of equatorial chloro ligands by polyfluoroaryl ligands makes reduction substantially more difficult, and confirm previously reported trends in that complexes having axial carboxylato ligands are more readily reduced than thoseHaving axial hydroxo ligand.
Journal ArticleDOI
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Michael Millward,John Zalcberg,James F. Bishop,Lorraine K. Webster,Allan Solomon Zimet,Danny Rischin,Guy C. Toner,Jacqui Laird,Walter Cosolo,Maureen E. Urch,Rene Bruno,Camille Loret,Robyn James,C. Blanc +13 more
TL;DR: The responses seen in this phase I study suggest a high degree of activity of this combination in previously untreated advanced NSCLC, and a dose for phase II studies is recommended.